Phase 1 study supports further development of inhaled respiratory therapy
June 25, 2026Research and Development Kither Biotech, respiratory therapy
Kither Biotech has reported positive results from a phase 1 study of KIT2014, an investigational inhaled therapy being developed for …
PL BioScience appoints Maik Jornitz to Board of Directors
June 24, 2026Manufacturing and Production PL Bioscience
PL BioScience has announced the appointment of Maik Jornitz to its board of directors, effective immediately. Jornitz brings technical expertise, …
Axplora consolidates liver disease API manufacturing in India
June 23, 2026Manufacturing and Production Axplora
Axplora has announced the consolidation of ursodeoxycholic acid (UDCA) manufacturing at its Vizag facility in India as part of a …
Data suggests avapritinib improves quality of life for patients with mastocytosis
June 22, 2026Research and Development mastocytosis
New data from the PIONEER study presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026 suggest …
Sandoz opens biosimilar development centre in Slovenia
June 19, 2026Business Development Sandoz, biosimilar development
Sandoz has opened a new biosimilar development centre in Ljubljana, Slovenia, as part of efforts to expand its in-house capabilities …
Codis announces three senior business development appointments
June 18, 2026Codis
Codis has announced three strategic appointments within its Business Development function. Pedro Fernandes Botas has been appointed as Business Development …
US laboratory approval supports launch of lung cancer blood test
June 17, 2026lung cancer blood test
UK based Cizzle Biotechnology has announced that its CIZ1B lung cancer blood test has been approved for use under Clinical …
Study to examine ways of improving diabetes care for younger adults
June 16, 2026diabetes
Researchers at Northumbria University are leading a £1.3m study aimed at helping GP practices improve care for young adults living …
Phase 2 endometriosis trial reaches recruitment milestone
June 15, 2026Research and Development Gesynta Pharma, endometriosis
Gesynta Pharma has announced that 50% of the target enrolment has been reached in its phase 2 NOVA trial evaluating …
NICE backs atogepant for acute migraine treatment
June 12, 2026NICE, atogepant, migraine treatment
NICE has issued Final Draft Guidance recommending AbbVie’s AQUIPTA (atogepant) as an option for the acute treatment of migraine, with …
Survey data highlight challenges in anaphylaxis treatment adherence
June 11, 2026European Academy of Allergy and Clinical Immunology (EAACI), anaphylaxis
New survey data presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress suggest many people at risk …
Hansa Biopharma appoints Fredrik Röök as VP Business Development
June 11, 2026Business Development Hansa Biopharma
Hansa Biopharma has announced that Fredrik Röök has been appointed as VP Business Development, as of 17 August. Röök will …
Sofinnova and AWS collaborate on AI tools for life sciences
June 10, 2026Research and Development AI, Amazon Web Services (AWS), Sofinnova
Sofinnova Partners has announced a collaboration with Amazon Web Services (AWS) aimed at expanding the use of AI across life …
First European approval given to non-opioid treatment for chronic low back pain
June 9, 2026Research and Development low back pain, non-opioid treatment
Germany has granted marketing authorisation to Exilby (VER-01) for the treatment of chronic low back pain with a neuropathic component, …
Closing the immunisation gap: partnership working that delivered at scale
June 5, 2026Business Services, Market Access Consultancy Visions4Health
As the UK healthcare system navigates a period of significant change, the path to successful market access is becoming increasingly …
Phase 2 study explores imaging approach for interstitial lung disease
June 5, 2026Research and Development interstitial lung disease
Serac Healthcare has presented phase 2 data suggesting its investigational imaging agent, 99mTc-maraciclatide, may help distinguish active inflammation from fibrosis …
Laverock secures funding for gene-control platform development
June 4, 2026Research and Development Laverock Therapeutics
Laverock Therapeutics has been awarded more than £2.2m in grant funding to support development of its gene-control platform and expand …
LifeArc and Elpida partner to advance gene therapies for ultra-rare childhood diseases
June 3, 2026Research and Development gene therapies
LifeArc has announced a partnership with Elpida Therapeutics to support development of gene therapies for three ultra-rare neurodegenerative diseases affecting …
Well Pharmacy and Alzheimer’s Society launch dementia partnership
June 2, 2026Research and Development dementia
Well Pharmacy has announced a partnership with Alzheimer’s Society aimed at improving support for people living with dementia and their …
China approves fruquintinib combination for kidney cancer
May 29, 2026Kidney cancer, Nephrology
China’s National Medical Products Administration (NMPA) has approved a combination of ELUNATE (fruquintinib) and TYVYT (sintilimab) for patients with advanced …
Latest content
FibroFind appoints Lee Borthwick as CEO
